HomeCompareBAX vs CAG

BAX vs CAG: Dividend Comparison 2026

BAX yields 2.28% · CAG yields 8.90%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CAG wins by $92.60M in total portfolio value
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
CAG
CAG
● Live price
8.90%
Share price
$15.73
Annual div
$1.40
5Y div CAGR
64.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$92.62M
Annual income
$80,567,478.04
Full CAG calculator →

Portfolio growth — BAX vs CAG

📍 CAG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXCAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + CAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
CAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
CAG
Annual income on $10K today (after 15% tax)
$756.52/yr
After 10yr DRIP, annual income (after tax)
$68,482,356.33/yr
At 15% tax rate, CAG beats the other by $68,482,347.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + CAG for your $10,000?

BAX: 50%CAG: 50%
100% CAG50/50100% BAX
Portfolio after 10yr
$46.32M
Annual income
$40,283,744.15/yr
Blended yield
86.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BAX right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
CAG
Analyst Ratings
1
Strong
5
Buy
14
Hold
4
Sell
Consensus: Hold
Price Target
$18.40
+17.0% upside vs current
Range: $15.00 — $22.00
Altman Z
1.5
Piotroski
3/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
CAG buys
0
No recent congressional trades found for BAX or CAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXCAG
Forward yield2.28%8.90%
Annual dividend / share$0.36$1.40
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%64.8%
Portfolio after 10y$20.6K$92.62M
Annual income after 10y$10.26$80,567,478.04
Total dividends collected$602.00$91.63M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Staples
Analyst consensusHoldHold
Analyst price target$19.75$18.40

Year-by-year: BAX vs CAG ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrCAG PortfolioCAG Income/yrGap
1← crossover$10,866$166.33$12,167$1,466.75$1.3KCAG
2$11,750$123.31$15,767$2,748.56$4.0KCAG
3$12,664$90.97$22,357$5,485.95$9.7KCAG
4$13,617$66.89$35,902$11,980.72$22.3KCAG
5$14,619$49.07$68,048$29,632.79$53.4KCAG
6$15,679$35.94$159,317$86,504.89$143.6KCAG
7$16,802$26.30$482,399$311,930.56$465.6KCAG
8$17,998$19.23$1,970,880$1,454,712.39$1.95MCAG
9$19,272$14.05$11,262,697$9,153,855.37$11.24MCAG
10$20,631$10.26$92,618,563$80,567,478.04$92.60MCAG

BAX vs CAG: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

CAGConsumer Staples

Conagra Brands, Inc., together with its subsidiaries, operates as a consumer packaged goods food company in North America. The company operates in four segments: Grocery & Snacks, Refrigerated & Frozen, International, and Foodservice. The Grocery & Snacks segment primarily offers shelf stable food products through various retail channels in the United States. The Refrigerated & Frozen segment provides temperature-controlled food products through various retail channels in the United States. The International segment offers food products in various temperature states through retail and foodservice channels outside of the United States. The Foodservice segment offers branded and customized food products, including meals, entrees, sauces, and various custom-manufactured culinary products packaged for restaurants and other foodservice establishments in the United States. The company sells its products under the Birds Eye, Duncan Hines, Healthy Choice, Marie Callender's, Reddi-wip, Slim Jim, Angie's BOOMCHICKAPOP, Duke's, Earth Balance, Gardein, and Frontera brands. The company was formerly known as ConAgra Foods, Inc. and changed its name to Conagra Brands, Inc. in November 2016. Conagra Brands, Inc. was founded in 1861 and is headquartered in Chicago, Illinois.

Full CAG Calculator →
📬

Get this BAX vs CAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.